Conventional chemotherapy often fails due to systemic toxicity and acquired drug resistance. To address this, I developed a multi-targeted therapeutic matrix using synergistic phytochemicals. Protein-protein interaction networks were utilized to identify primary melanoma targets. High-resolution, multi-omic in silico modeling validated the in vitro results, revealing that specific compounds achieved a 100,000x increase in binding efficacy compared to three standard-of-care chemotherapies. Within laboratory vitro assays, the Group 8 matrix achieved a 91% cell death within melanoma. The combination achieved a significant Selectivity Index (SI) of 17.97, while individual compounds demonstrated up to 40x greater selectivity compared conventional chemotherapeutics. No adverse biochemical interactions were observed, confirming a wide therapeutic window. This clinically feasible research provides a scalable, low-cost ($0.0132/mL) pharmaceutical alternative that prioritizes selective cytotoxicity for accessible oncology. The treatment is adaptable for IV administration in systemic or metastatic cases, while topical applications offer an easy, non-invasive method for localized primary tumors.